KYM-001, first-in-class oral IRAK4 protein degraders, induce tumor regression in a xenograft model of MYD-88 mutant ABC DLBCL alone and in combination with BTK inhibition
Area of Focus
Oncology
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
